UY35784A - Formas farmacéuticas de dosificación que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h- 1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio - Google Patents

Formas farmacéuticas de dosificación que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h- 1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio

Info

Publication number
UY35784A
UY35784A UY0001035784A UY35784A UY35784A UY 35784 A UY35784 A UY 35784A UY 0001035784 A UY0001035784 A UY 0001035784A UY 35784 A UY35784 A UY 35784A UY 35784 A UY35784 A UY 35784A
Authority
UY
Uruguay
Prior art keywords
triazol
pyrimidin
dosage forms
olate
sodium
Prior art date
Application number
UY0001035784A
Other languages
English (en)
Inventor
Formell Michael
Dr Gabriele Winter
Dr Heike Neumann
Dr Klaus Benke
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49356354&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35784(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY35784A publication Critical patent/UY35784A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas farmacéuticas de dosificación sólidas para administración oral que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1H-pirazol-5-olato de sodio (principio activo (I)),caracterizadas por que se libera el principio activo (I) y también a procedimientos para su preparación, a su uso como medicamentos y también a su uso para prevención, prevención secundaria o tratamiento de trastornos, en particular trastornos cardiovasculares, insuficiencia cardíaca, anemia, trastornos renales crónicos e insuficiencia renal.
UY0001035784A 2013-10-17 2014-10-15 Formas farmacéuticas de dosificación que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h- 1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio UY35784A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13189145 2013-10-17

Publications (1)

Publication Number Publication Date
UY35784A true UY35784A (es) 2015-05-29

Family

ID=49356354

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035784A UY35784A (es) 2013-10-17 2014-10-15 Formas farmacéuticas de dosificación que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h- 1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio

Country Status (35)

Country Link
US (1) US9827198B2 (es)
EP (1) EP3057580B1 (es)
JP (1) JP6525979B2 (es)
KR (1) KR102330953B1 (es)
CN (1) CN105636580B (es)
AP (1) AP2016009135A0 (es)
AR (1) AR098064A1 (es)
AU (1) AU2014336389B2 (es)
BR (1) BR112016007588A2 (es)
CA (1) CA2927437C (es)
CL (1) CL2016000857A1 (es)
CU (1) CU24515B1 (es)
DK (1) DK3057580T3 (es)
DO (1) DOP2016000078A (es)
EA (1) EA032932B1 (es)
ES (1) ES2868228T3 (es)
GT (1) GT201600072A (es)
HR (1) HRP20210691T1 (es)
HU (1) HUE054107T2 (es)
IL (1) IL244933B (es)
JO (1) JO3645B1 (es)
LT (1) LT3057580T (es)
MA (1) MA38974B2 (es)
MX (1) MX2016004628A (es)
MY (1) MY190202A (es)
NI (1) NI201600054A (es)
PE (1) PE20160669A1 (es)
PH (1) PH12016500716A1 (es)
SA (1) SA516370940B1 (es)
SI (1) SI3057580T1 (es)
TN (1) TN2016000135A1 (es)
TW (1) TWI746418B (es)
UA (1) UA119855C2 (es)
UY (1) UY35784A (es)
WO (1) WO2015055564A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202023565A (zh) * 2018-08-31 2020-07-01 日商安斯泰來製藥股份有限公司 經口投予用醫藥組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
US8778392B2 (en) * 2007-03-13 2014-07-15 Dainippon Sumitomo Pharma Co., Ltd. Oral disintegrating tablet
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
TN2016000135A1 (en) 2017-10-06
CU20160048A7 (es) 2016-10-28
CN105636580B (zh) 2020-03-31
SI3057580T1 (sl) 2021-07-30
CU24515B1 (es) 2021-05-12
MA38974B2 (fr) 2020-11-30
PE20160669A1 (es) 2016-08-04
EA201690788A1 (ru) 2016-09-30
TW201607568A (zh) 2016-03-01
EA032932B1 (ru) 2019-08-30
MX2016004628A (es) 2016-08-01
MY190202A (en) 2022-04-04
CA2927437C (en) 2022-06-28
US9827198B2 (en) 2017-11-28
DOP2016000078A (es) 2016-08-15
AP2016009135A0 (en) 2016-04-30
AR098064A1 (es) 2016-04-27
IL244933A0 (en) 2016-05-31
GT201600072A (es) 2018-12-19
TWI746418B (zh) 2021-11-21
EP3057580B1 (de) 2021-02-24
MA38974A1 (fr) 2017-05-31
DK3057580T3 (da) 2021-05-10
AU2014336389A1 (en) 2016-05-12
BR112016007588A2 (pt) 2017-09-12
KR20160068784A (ko) 2016-06-15
CN105636580A (zh) 2016-06-01
JP6525979B2 (ja) 2019-06-05
LT3057580T (lt) 2021-04-12
WO2015055564A1 (de) 2015-04-23
CA2927437A1 (en) 2015-04-23
JP2016538256A (ja) 2016-12-08
NI201600054A (es) 2016-09-21
JO3645B1 (ar) 2020-08-27
PH12016500716B1 (en) 2016-06-20
HUE054107T2 (hu) 2021-08-30
NZ718063A (en) 2021-06-25
HRP20210691T1 (hr) 2021-06-11
EP3057580A1 (de) 2016-08-24
PH12016500716A1 (en) 2016-06-20
US20160256394A1 (en) 2016-09-08
IL244933B (en) 2020-11-30
KR102330953B1 (ko) 2021-11-26
AU2014336389B2 (en) 2020-01-30
ES2868228T3 (es) 2021-10-21
CL2016000857A1 (es) 2016-11-25
SA516370940B1 (ar) 2019-11-20
UA119855C2 (uk) 2019-08-27

Similar Documents

Publication Publication Date Title
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
BR112015018168A2 (pt) inibidores de rock suaves
MY166288A (en) Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt
MX2013003635A (es) Compuestos de n-heteroarilo.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
PH12014502366B1 (en) Injectable formulation
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MY174729A (en) Pharmaceutical combination drug
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
EA201691231A1 (ru) Фармацевтические лекарственные формы
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
UY35784A (es) Formas farmacéuticas de dosificación que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4-(1h- 1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
BR112016015175A2 (pt) Formulação farmacêutica, método para a fabricação de uma formulação farmacêutica compreendendo sildenafila e clomipramina e comprimido
BR112014032264A8 (pt) Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20221107